18 results
8-K
EX-10.2
ARAV
Aravive Inc
3 Jun 22
Aravive Appoints Rudy Howard as Chief Financial Officer
4:06pm
liabilities, losses, damages, costs, and other expenses (including attorneys’ and expert witnesses’ costs and fees) arising from or relating to any
8-K
EX-99.2
ARAV
Aravive Inc
19 Nov 20
Aravive Announces Phase 3 Trial Design for AVB-500 in Platinum Resistant Ovarian Cancer
7:10am
than those for AXL- or GAS6- patients (51% vs. 75%; P=0.028; 53% vs. 72%; P=0.040) Linger et al. 2012. Expert Opin Ther Targets. 2010 October ; 14(10
8-K
EX-10.4
ARAV
Aravive Inc
9 Jan 20
Aravive Announces Management Changes
4:59pm
and all liabilities, losses, damages, costs, and other expenses (including attorneys’ and expert witnesses’ costs and fees) arising from or relating to any
424B5
g2osx70 m5
27 Nov 19
Prospectus supplement for primary offering
4:07pm
424B5
o6azxll5pq1i9
26 Nov 19
Prospectus supplement for primary offering
5:18pm
S-4
EX-10.1
oxj3 rm6q6uj5zzv
3 Aug 18
Registration of securities issued in business combination transactions
5:26pm
S-4
EX-10.8
9kma35g5 6k8
3 Aug 18
Registration of securities issued in business combination transactions
5:26pm
S-4
EX-10.6
0hamfnl
3 Aug 18
Registration of securities issued in business combination transactions
5:26pm
S-4
5yogwaiy9eidzm
3 Aug 18
Registration of securities issued in business combination transactions
5:26pm
424B4
kqwe0foy05lqf32
22 Jan 15
Prospectus supplement with pricing info
12:00am
424B4
1e7mj9ndk15kd3e5aixi
21 Mar 14
Prospectus supplement with pricing info
12:00am
DRS
69f7mygk1uvq
10 Jan 14
Draft registration statement
12:00am
- Prev
- 1
- Next